ICU Medical, Inc. (NASDAQ:ICUI) shares have more than 10.11 percent upside potential from the existing levels. This is based on the revised price target of KeyBanc at $ 218.00 on the stock. Incidentally, the brokerage raised its price objective by $ 19 from its earlier level of $ 199.00. However, KeyBanc has maintained its Overweight rating on the stock, Benzinga reported.
Shares of ICU Medical, Inc. traded up $ 0.12 or 0.06 percent on Wednesday, reaching $ 198.10 with volume of 14.90 thousand shares. The stock opened positive for the day at $ 202.65, after closing the previous day trading at $ 197.98. According to the previous trading day, closing price of $ 197.98, representing a 32.97 % increase from the 52 week low of $ 148.89 and a 16.29 % decrease over the 52 week high of $ 236.51.
With respect to the key metrics, ICU Medical, Inc. stock has advanced $ 4.68 or 2.00 percent, reaching $ 193.42 during the simple moving average (SMA) period of 200 days. Similarly, the stock has increased $ 9.98 or 5.00 percent, before arriving at $ 188.12 during the SMA50-day period.
Moving forward, analysts surveyed by Thomson Reuters are expecting ICU Medical to report third quarter income of $ 1.31 per share from revenue of $ 284.70 million. For the full year, analysts anticipate top line of $ 1184.10 million, while looking forward to income of $ 6.40 per share bottom line.
ICU Medical, Inc. develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patients vein.
